Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 209   

Articles published

SNY 51.47 0.00 (0.00%)
price chart
For Sanofi SA (ADR) (SNY) Chronic Diseases Present the Future Focus
In an interview with CNBC, Chris Viehbacher, the CEO of Sanofi SA (ADR) (NYSE:SNY), discussed the steps that big pharma companies like Sanofi SA (ADR) (NYSE:SNY) are taking to tackle chronic diseases that are a major cause of worry for the aging ...
Related articles »  
FDA Accepts Sanofi's NDA For Toujeo
Sanofi SA (SNY) announced today that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for its experimental therapy drug, Toujeo.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) signs Deal with Merrimack Pharmaceuticals Inc ...
Tomahawk, WI 06/23/2014 (Basicsmedia) - Global healthcare company Sanofi SA (ADR) (NYSE:SNY) and biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have reached an understanding allowing Merrimack to develop and ...
Related articles »  
Traders Recap- Haemonetics Corporation (NYSE:HAE), Sanofi SA (ADR) (NYSE ...
Sanofi SA (ADR)(NYSE:SNY) traded 1.46million shares in the last business day while the average volume of the stock remained 991,401.00 shares.
Investor's Watch List - Sanofi SA (ADR) (SNY), XOMA Corp (XOMA), AVEO ...
Birmingham, West Midlands - (TechSonian) �July 12, 2014 - Sanofi SA (ADR) (NYSE:SNY) declared the positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic ...
Related articles »  
Stocks On the move: Sanofi SA (ADR) (NYSE:SNY), Forest Laboratories (NYSE ...
Sanofi SA (NYSE:SNY) had its neutral rating reissued by analysts at Zacks. The firm currently has a $57.00 target price on the stock.
Related articles »  
Stock Alert: Sanofi SA (ADR) (NYSE:SNY), Amgen (NASDAQ:AMGN), Bio-Rad ...
Co and Sanofi SA (ADR) (NYSE:SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD.
Notable Stocks: Merck & Co. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY), Eli ...
This third party may exploit these patent rights independently or in conjunction with another third party. On last trading day, Sanofi SA (ADR) (NYSE:SNY)'s stock traded at beginning with a price of $53.30 and throughout the trading session climbed at ...
Market Movers: Sanofi SA (ADR) (NYSE:SNY), GlaxoSmithKline plc (ADR ...
On 23 JUNE Sanofi SA (ADR) (NYSE:SNY) and biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) have reached an understanding allowing Merrimack to develop and commercialize monoclonal antibody drug MM-121.
Trader's Alert: Nektar Therapeutics (NASDAQ:NKTR), AstraZeneca plc (ADR ...
Zacks reiterated their neutral rating on shares of Sanofi SA (NYSE:SNY) in a research report released on Friday morning. Zacks currently has a $57.00 price objective on the stock.